Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1990 1
1992 1
1993 1
1995 1
1997 3
1998 1
2000 1
2001 1
2002 3
2003 1
2005 5
2006 2
2008 1
2009 1
2010 2
2011 4
2012 5
2013 4
2014 4
2015 2
2016 3
2017 4
2018 3
2019 6
2020 2
2021 1
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Squamous Cell Carcinoma of Unknown Primary"
Page 1
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Kiyota N, et al. J Clin Oncol. 2022 Jun 20;40(18):1980-1990. doi: 10.1200/JCO.21.01293. Epub 2022 Mar 1. J Clin Oncol. 2022. PMID: 35230884 Free PMC article. Clinical Trial.
PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m(2)). ...The primary end point of phase II was the …
PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of t …
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed and cisplatin, compared with pemetrexed and cisplatin alone, for the treatment of patients with locally advanced or metastatic EGFR-mutated non-small-cell lung c …
We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed and cisplatin, compared with pemetrexed an …
Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer.
Bakst RL, Glastonbury CM, Parvathaneni U, Katabi N, Hu KS, Yom SS. Bakst RL, et al. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1109-1124. doi: 10.1016/j.ijrobp.2018.12.009. Epub 2018 Dec 15. Int J Radiat Oncol Biol Phys. 2019. PMID: 30562546 Review.
Perineural invasion (PNI), the neoplastic invasion of nerves, is a common pathologic finding in head and neck cancer that is associated with poor clinical outcomes. PNI is a histologic finding of tumor cell infiltration and is distinct from perineural tumor spread (PNTS), …
Perineural invasion (PNI), the neoplastic invasion of nerves, is a common pathologic finding in head and neck cancer that is associated with …
Treatment outcomes of unknown primary squamous cell carcinoma of the head and neck.
Hung YH, Liu SA, Wang CC, Wang CP, Jiang RS, Wu SH. Hung YH, et al. PLoS One. 2018 Oct 18;13(10):e0205365. doi: 10.1371/journal.pone.0205365. eCollection 2018. PLoS One. 2018. PMID: 30335795 Free PMC article.
BACKGROUND: Treatment modality of unknown primary squamous cell carcinoma of the head and neck (SCCHN) remains controversial. OBJECTIVES: To evaluate the treatment outcomes and prognostic factors of unknown primary SCCHN. MATERIALS …
BACKGROUND: Treatment modality of unknown primary squamous cell carcinoma of the head and neck (SCCHN) re …
The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer.
Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S. Gruhl JD, et al. Cancer Med. 2020 Mar;9(5):1703-1711. doi: 10.1002/cam4.2851. Epub 2020 Jan 16. Cancer Med. 2020. PMID: 31945808 Free PMC article.
BACKGROUND: The prognosis for nonmetastatic, primary pancreatic squamous cell carcinoma (SCC) is thought to be poor compared with adenocarcinoma (AC); however, this is based on limited data. ...CONCLUSIONS: Nonmetastatic pancreatic SCC presents with mo …
BACKGROUND: The prognosis for nonmetastatic, primary pancreatic squamous cell carcinoma (SCC) is thought to be p …
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu Z, Zhao W, Lin Q, Yang H, Zheng X, Zhou J, Huang G, Li L, Li J, Zhang Z, Zhou G, Gu D, Du M, Mo M, Jia H, Zhang Z, Zhao K. Ai D, et al. JAMA Netw Open. 2022 Feb 1;5(2):e220120. doi: 10.1001/jamanetworkopen.2022.0120. JAMA Netw Open. 2022. PMID: 35188552 Free PMC article. Clinical Trial.
However, which among these 3 regimens provides the best prognosis with minimum adverse events is still unknown. OBJECTIVE: To compare the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy in patients with esophageal …
However, which among these 3 regimens provides the best prognosis with minimum adverse events is still unknown. OBJECTIVE: To compare …
Predictors of survival and recurrence after primary surgery for cervical metastasis of unknown primary.
Cho WK, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY. Cho WK, et al. J Cancer Res Clin Oncol. 2020 Apr;146(4):925-933. doi: 10.1007/s00432-019-03111-x. Epub 2019 Dec 19. J Cancer Res Clin Oncol. 2020. PMID: 31858242
PURPOSE: Cervical metastasis from unknown primary (CUP) is commonly classified as an advanced overall stage. ...Therefore, we evaluated the prognostic values of p16 immuno-positivity in LN and other clinicopathological factors in patients with squamous …
PURPOSE: Cervical metastasis from unknown primary (CUP) is commonly classified as an advanced overall stage. ...Therefo …
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M. Nilsson K, et al. Ann Oncol. 2023 Nov;34(11):1015-1024. doi: 10.1016/j.annonc.2023.08.010. Epub 2023 Aug 30. Ann Oncol. 2023. PMID: 37657554 Free article. Clinical Trial.
The NeoRes II trial is the first randomised trial to compare standard to prolonged TTS after nCRT for oesophageal cancer. PATIENTS AND METHODS: Patients with resectable, locally advanced oesophageal cancer were randomly assigned to standard delay of surgery of 4-6 w …
The NeoRes II trial is the first randomised trial to compare standard to prolonged TTS after nCRT for oesophageal cancer. PATIENTS AND METHO …
Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study.
Fountzilas G, Skarlos D, Nikolaou A, Kalogera-Fountzila A, Tzitzikas J, Kosmidis P, Makrantonakis P, Samantas E, Karpasitis N, Bacoyiannis H, et al. Fountzilas G, et al. Tumori. 1995 Sep-Oct;81(5):354-8. doi: 10.1177/030089169508100510. Tumori. 1995. PMID: 8804453 Review.
AIMS AND BACKGROUND: To improve local control in patients with locally advanced inoperable head and neck cancer we administered carboplatin concurrently with radiation. ...Histology was squamous cell carcinoma in all cases. All patients w …
AIMS AND BACKGROUND: To improve local control in patients with locally advanced inoperable head and neck cancer we admi …
Prognostic value of human papillomavirus in anal squamous cell carcinoma.
Ravenda PS, Magni E, Botteri E, Manzotti M, Barberis M, Vacirca D, Trovato CM, Dell'Acqua V, Leonardi MC, Sideri M, Fazio N, Zampino MG. Ravenda PS, et al. Cancer Chemother Pharmacol. 2014 Nov;74(5):1033-8. doi: 10.1007/s00280-014-2582-x. Epub 2014 Sep 11. Cancer Chemother Pharmacol. 2014. PMID: 25209946
PURPOSE: Anal cancer is an uncommon malignancy, but its incidence is increasing worldwide. Chemoradiation is the standard primary treatment for patients with loco-regional limited disease. ...Human papillomavirus (HPV) is present in around 80 % of anal cancers, but its pro …
PURPOSE: Anal cancer is an uncommon malignancy, but its incidence is increasing worldwide. Chemoradiation is the standard primary tre …
70 results